ObesityWeek attendees crowd around a poster with Phase 1 data for Viking's oral weight loss drug VK2735. (Credit: Kyle LaHucik for Endpoints News)

November 3, 2024 09:18 PM ESTUpdated 06:28 AM

Pharma

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Kyle LaHucik

Senior Reporter

SAN ANTONIO — Viking Therapeutics’ highly anticipated readout of its oral anti-obesity pill showed a placebo-adjusted weight loss of 6.8% after four weeks, sticking the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Rare disease biopharma companies weigh in on FDA's new innovation hub

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial